""Thank you. So yes, this is a very good question, and we continue to fit the pieces of the jigsaw puzzle together in terms of ensuring that we have each of the different stages of production aligned. As we look at each of these capacity growth initiatives, we look at what is the optimum step in the first instance. So for example, as we think about moving through from the current sort of 7,000 tonnes up to, say, the 12,000 tonnes, we could have said, well, just go to say 10,000 tonnes in the first instance. But it -- project planning, design and efficiency said best to go to the 12,000 tonnes.
In terms of the Kalgoorlie facility, our first milestone was that we needed to make sure on a risk management basis that we were able to at least replace what we did in Malaysia. But as the project has progressed, we’ve actually made decisions, and we’ve disclosed those previously to allow us to confidently provide the target uplift in nameplate capacity. Now further investment in that whilst we are still in ongoing discussions with the regulator in Malaysia, we feel would not be prudent. However, as I indicated, the Kalgoorlie facility is sort of a really substantial foundational facility, which gives us room to grow both in terms of capacity and activity. But we’re not positioned to disclose specifically how that would operate today, but we are in a position to disclose the 9,000 tonnes per annum.""
Extract from transcript of full year results briefing, courtesy of Seeking Alpha. Q&A session, Amanda's response to a question around capacity. Yes Mikaj, it has been confusing. Good to see you here again Aus.
- Forums
- ASX - By Stock
- Ann: FY23 Financial Results Presentation
LYC
lynas rare earths limited
Add to My Watchlist
3.48%
!
$8.88

""Thank you. So yes, this is a very good question, and we...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$8.88 |
Change
-0.320(3.48%) |
Mkt cap ! $8.306B |
Open | High | Low | Value | Volume |
$9.44 | $9.44 | $8.86 | $61.13M | 6.800M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 225 | $8.88 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$8.91 | 24100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2 | 8.880 |
1 | 80 | 8.850 |
1 | 508 | 8.830 |
1 | 675 | 8.820 |
6 | 3145 | 8.800 |
Price($) | Vol. | No. |
---|---|---|
8.930 | 200 | 1 |
8.950 | 200 | 1 |
8.960 | 650 | 1 |
8.990 | 164 | 1 |
9.020 | 1100 | 1 |
Last trade - 16.11pm 27/06/2025 (20 minute delay) ? |
Featured News
LYC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online